Original Article Link --> https://area1255.blogspot.com/2016/11/masteron-vs-andractim-for-estrogen...

During a steroid cycle, Estrogen control is crucial to both minimizing suppression, maintaining gains, ensuring solid, lean gains, and eliminating the risk of water retention and gyno - or male breast growth.

The question, is whether Masteron or Andractim compare better in terms of reducing current incidence of ''gyno'' and performing the estrogen control duties that a DHT-compound can play.
Out of those options, evidence is most important, and strongly on the side of Andractim for 'local estrogen control'. Andractim favours the treatment of gynecomastia (male breast growth) better than Masteron (drostanolone propionate/enanthate) does. However, Masteron ranks better at hardening gains and increasing fat loss/water loss. Masteron also appears to have a stronger effect on libido.

Masteron ranks a bit better in increasing strength, while Andractim seems to produce quicker effects on gyno reduction.

If you were to compare the two, the factors you would look at are...

*-:Are you looking for a Gynecomastia solution primarily?
*-:Are you looking to cut serious water, and are you also stacking Deca (Nandrolone) with your cycle?
*-:Are you looking for strength increases?
If you answered "Yes" to the first question then Andractim is the way to go. If you answered Yes to the other two questions, then Masteron is the one you want. So that's that, ultimately it comes down to what YOUR goals are and your current cycle or regimen, if you aren't using anabolic steroids at all and are just looking for a solution to male breast growth then Andractim is your best friend.

With all this said and done, there are much more 'solid' sources of E2-control, and Arimidex should still be first line. The point of this write-up is to confine the two distinct roles these compounds share if they are to be seen as estrogen-reduction agents. It does not mean they are a replacement for a good old-fashioned estrogen control Protocol. Like said, and being brief as possible, Masteron nor Andractim are estrogen-blocking Agents by definition, but they certainly share some of the receptor-level hallmarks of SERMs.

These agents are to be used when and where they can be applied. They aren't supplements, they should not be treated as such. Anyone can and is capable of abusing these substances, they have their benefits, but over-use will undoubtedly lead to suppression.

Lastly, Masteron as an aphrodisiac agent does not necessarily come from its estrogen reducing abilities, but rather, it comes down to its direct actions as an androgenic agent. It is able to provide a rise in libido by ensuring androgens can hit target organs and crucial brain regions like the Hypothalamus...and possibly the limbic system. Masteron's effects on erectile quality are related to DHT-simulated nitric oxide release and nourishment of the Pelvic Ganglia nerve fibres. I say simulated because it is not endogenous or ''natural'' DHT doing the work but a synthetic compound acting like DHT.

SOURCES
The Vital Three
ThinkSteroids (Meso) : DHT (Dihydrotestosterone)
ThinkSteroids (Meso) : Masteron (Drostanolone Propionate)
Steroid.com : Steroid Profiles - Andractim (Topical Dihydrotestosterone)

J Clin Endocrinol Metab. 2002 Apr;87(4):1467-72.
The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study.

J Urol. 2008 Feb;179(2):684-8. Epub 2007 Dec 20.
The efficacy of dihydrotestosterone transdermal gel before primary hypospadias surgery: a prospective, controlled, randomized study.

J Clin Endocrinol Metab. 2011 Feb; 96(2): 430–437.
Published online 2010 Dec 22. doi: 10.1210/jc.2010-1865
Dihydrotestosterone Administration Does Not Increase Intraprostatic Androgen Concentrations or Alter Prostate Androgen Action in Healthy Men: A Randomized-Controlled Trial

J Clin Endocrinol Metab. 2001 Sep;86(9):4078-88.
A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency.

Maturitas. 1985 Sep;7(3):281-7.
Long-term transdermal dihydrotestosterone therapy: effects on pituitary gonadal axis and plasma lipoproteins.

Successful Percutaneous Dihydrotestosterone Treatment of Gynecomastia Occurring during Highly Active Antiretroviral Therapy: Four Cases and a Review of the Literature

Dihydrotestosterone for HAART-associated breast enlargement in men